Potent anti-obese principle from Rosa canina: Structural requirements and mode of action of trans-tiliroside

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 11, 2007, Pages 3059-3064

  Ninomiya, Kiyofumi ^a,b   Matsuda, Hisashi ^a   Kubo, Mizuho ^a   Morikawa, Toshio ^a,b   Nishida, Norihisa ^a,c   Yoshikawa, Masayuki ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KINKI UNIVERSITY   (Japan)

^c Morishita Jintan Co Ltd   (Japan)

Author keywords

Anti obesity; PPAR ; Rosa canina; trans Tiliroside; Visceral fat

Indexed keywords

ANTIOBESITY AGENT; ASTRAGALIN; GLUCOSE; PARA COUMARIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TILIROSIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG INHIBITION; DRUG ISOLATION; DRUG POTENCY; DRUG STRUCTURE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; INTRAABDOMINAL FAT; LIVER WEIGHT; MOUSE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; ROSACEAE;

ACETONE; ANIMALS; ANTI-OBESITY AGENTS; BENZOPYRANS; BODY WEIGHT; COUMARIC ACIDS; INTRA-ABDOMINAL FAT; KAEMPFEROLS; LIVER; MICE; PLANT EXTRACTS; PPAR ALPHA; RNA, MESSENGER; ROSA; STRUCTURE-ACTIVITY RELATIONSHIP; WATER; WEIGHT GAIN;

MUS; ROSA CANINA;

EID: 34247895642     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.03.051     Document Type: Article

References (32)

1. Larsson B., Bjorntorp P., and Tibblin G. Int. J. Obes. 5 (1981) 97
2. Hartz A.J., Rupley Jr. D.C., Kallhoff R.D., and Rimm A.A. Prev. Med. 12 (1983) 351
3. Flegal K.M., Carroll M.D., Kuczmarski R.J., and Johnson C.L. Int. J. Obes. Relat. Metab. Disord. 22 (1998) 39
4. Mokdad A.H., Serdula M.K., Dietz W.H., Bowman B.A., Marks J.S., and Koplan J.P. JAMA 282 (1999) 1519
5. Must A., Spadano J., Coakley E.H., Field A.E., Colditz G., and Dietz W.H. JAMA 282 (1999) 1523
6. Allison D.B., Fontaine K.R., Manson J.E., Stevens J., and VanItallie T.B. JAMA 282 (1999) 1530
7. Matsuzawa Y. FEBS Lett. 580 (2006) 2917
8. Yoshikawa M., Morikawa T., Matsuda H., Tanabe G., and Muraoka O. Bioorg. Med. Chem. 10 (2002) 1547
9. Matsuda H., Morikawa T., Toguchida I., and Yoshikawa M. Chem. Pharm. Bull. 50 (2002) 788
10. Matsuda H., Morikawa T., Toguchida I., Harima S., and Yoshikawa M. Chem. Pharm. Bull. 50 (2002) 972
11. Yoshikawa M., Murakami T., Ishiwada T., Morikawa T., Kagawa M., Higashi Y., and Matsuda H. J. Nat. Prod. 65 (2002) 1151
12. Shimoda H., Ninomiya K., Nishida N., Yoshino T., Morikawa T., Matsuda H., and Yoshikawa M. Bioorg. Med. Chem. Lett. 13 (2003) 223
13. Morikawa T., Kishi A., Pongpiriyadacha Y., Matsuda H., and Yoshikawa M. J. Nat. Prod. 66 (2003) 1191
14. Yoshikawa M., Pongpiriyadacha Y., Kishi A., Kageura T., Wang T., Morikawa T., and Matsuda H. Yakugaku Zasshi 123 (2003) 871
15. Morikawa T., Xu F., Kashima Y., Matsuda H., Ninomiya K., and Yoshikawa M. Org. Lett. 6 (2004) 869
16. Morikawa T., Xu F., Ninomiya K., Matsuda H., and Yoshikawa M. Chem. Pharm. Bull. 52 (2004) 494
17. Ninomiya K., Matsuda H., Shimoda H., Nishida N., Kasajima N., Yoshino T., Morikawa T., and Yoshikawa M. Bioorg. Med. Chem. Lett. 14 (2004) 1943
18. Yoshikawa M., Morikawa T., Yamamoto K., Kato Y., Nagatomo A., and Matsuda H. J. Nat. Prod. 68 (2005) 1360
19. Matsuda H., Yoshikawa M., Morikawa T., Tanabe G., and Muraoka O. J. Trad. Med. 22 Suppl. 1 (2005) 145 and literatures cited therein
20. Kuroyanagi M., Fukuoka M., Yoshihira K., Natori S., and Yamasaki K. Chem. Pharm. Bull. 26 (1978) 3594
21. Tsukamoto S., Tomise K., Aburatani M., Onuki H., Hirorta H., Ishiharajima E., and Ohta T. J. Nat. Prod. 67 (2004) 1839
22. Kubo I., and Yokokawa Y. Phytochemistry 31 (1992) 1075
23. Yeo H., Chin Y.-W., Park S.-Y., and Kim J. Arch. Pharm. Res. 27 (2004) 287
24. Shen Y.-C., Hsieh P.-W., and Kuo Y.-H. Phytochemistry 48 (1998) 719
25. 11 were also used for the pharmacological evaluation.
26. Matsuda H., Ninomiya K., Shimoda H., and Yoshikawa M. Bioorg. Med. Chem. 10 (2002) 707
27. Rao Y.K., Fang S.H., and Tzeng Y.M. Biol. Pharm. Bull. 28 (2005) 99
28. Sala A., Recio M.C., Schinella G.R., Manez S., Giner R.M., Cerda-Nicolas M., and Rosi J.L. Eur. J. Pharmacol. 461 (2003) 53
29. Lee S.Y., Min B.S., Kim J.H., Lee J., Kim T.J., Kim C.S., Kim Y.H., and Lee H.K. Phytother. Res. 19 (2005) 273
30. 2O, and the TG concentration in the suspension was determined using Triglyceride E-test Wako.
31. For statistical analysis, one-way analysis of variance followed by Dunnett's test was used. Probability (P) values of less than 0.05 were considered significant.
32. 12-18 (0.5 μg/μL) as a first-strand primer. The following specific primers (Invitrogen) were used: PPAR-α mRNA, sense 5′ATGCCAGTACTGCCGTTTTC3′, and antisense 5′GGCCTTGACCTTGTTCATGT3′; β-actin 5′GGGAAATCGTGCGTGACAT3′ and antisense 5′CAGGAGGAGCAATGATCTC3′. Reverse transcription was performed at 42 °C for 30 min. Thermocycling parameters were as follows: denaturation at 95 °C for 1 min and 19 cycles for PPAR-α and 20 cycles for β-actin, consisting of incubations at 95 °C for 1 min, 58 °C for 1 min, and 72 °C for 2 min. After PCR, 15 μL of the reaction mixture was subjected to electrophoresis on a 2% agarose gel and visualized by ethidium bromide staining.